Mark Cziraky, PharmD, CLS, vice president of research for Healthcore, explains why biosimilar utilization in the United States is low.
Transcript:
Are there gaps in knowledge about biosimilars that are impacting decision-making by stakeholders?
I think we’re not seeing the utilization because there’s not a lot marketed yet, so it’s tough to see what’s happening out there in the marketplace after you get real-world use of these products. From a standpoint of the approvals and the trials, you know they’re of course safe and effective from the standpoint of being biosimilars. The other piece of it is there may be some concerns about safety and the immunogenicity, but I don’t believe that’s having a significant impact on the use currently. It’s really just the amount that are available for use. Also, again, because there’s not a lot of competition in the marketplace, the ability to see significant cost-reductions that is hoped by these therapies has not yet been reached.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.